# Cabaletta Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cabaletta-bio

- Industry: Biotechnology
- Headquarters: Philadelphia, US
- Website: www.cabalettabio.com
- Total disclosed funding: $88M
- Latest round: Series B (Jan 3, 2019)
- Investors on record: 7

## About

Cabaletta Bio Inc. is a biotechnology company focused on developing innovative cell therapies for autoimmune diseases, striving to address significant unmet medical needs with its advanced products.Cabaletta Bio Inc., founded in 2017 and headquartered in Philadelphia, US, specializes in cell therapies targeting autoimmune diseases. The company was established by Aimee P., Michael Milone, and Steven Nichtberger, who have a history of entrepreneurship in the biotech sector. Cabaletta has engaged in 4 deals to date, with its most recent funding round being a Private Placement that raised USD 35.00 mn on December 8, 2022, led by Adage Capital Management, Cormorant Asset Management, and Venrock. The total amount raised by the company now stands at USD 35.00 mn.Cabaletta Bio, Inc. primarily focuses on developing innovative cell therapies for patients suffering from autoimmune diseases. Their core product, CABA-201, is an investigational CD19 Chimeric Antigen Receptor (CAR) T cell therapy designed to target diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris. This therapy aims to achieve deep and durable responses by transiently eliminating B cells to potentially reset the immune system and promote remission. Currently, Cabaletta is conducting its RESET™ clinical trials, which are pivotal in assessing the safety and efficacy of CABA-201. The company's therapeutic offerings are aimed at addressing significant unmet medical needs in the autoimmune disease space, with a focus on markets in North America and Europe, where these conditions are prevalent and treatment options are limited.Cabaletta Bio generates revenue through its clinical development programs and partnerships within the biotechnology sector, particularly focused on the commercialization of CABA-201. Revenue transactions typically arise from collaborations and agreements with healthcare institutions and research organizations involved in clinical trials. These relationships often encompass shared research agreements or potential licensing arrangements that can leverage Cabaletta's proprietary technologies. As the company advances its clinical trials and approaches potential regulatory approvals, it may attract further funding through public offerings or private investments, aligning with strategic goals to enhance its product pipeline. Although specific pricing plans for their therapies have not been disclosed, the focus remains on creating accessible and transformative treatment options for patients, reinforcing the company's commitment to addressing autoimmune diseases effectively.Cabaletta Bio plans to utilize the recent funding of USD 35.00 mn to complete preclinical development and submit the Investigational New Drug (IND) application for CABA-201, while also initiating its clinical development in multiple indications. Additionally, the company aims to advance ongoing clinical studies for its DSG3-CAART and MuSK-CAART product candidates. The strategic focus includes targeting expansion into new geographic markets in North America and Europe by 2024, where there is a significant demand for innovative therapies addressing autoimmune diseases.

## Funding rounds

- Series B, Jan 3, 2019, $50M — 5AM Ventures, Adage Capital Management, Redmile Group, Deerfield Management, Boxer Capital, Cormorant Capital
- Series A, Oct 1, 2018, $38M — 5AM Ventures, Adage Capital Management, University of Pennsylvania Pension Fund

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Adage Capital Management — Series A, Series B
- University of Pennsylvania Pension Fund — Series A
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- Cormorant Capital — Series B